I. Mata

Psychosis Endophenotypes: A Gene-Set-Specific Polygenic Risk Score Analysis
20234 citationsauthor #30
Looking back the importance of genetics in a patient with Parkinson disease and deep brain stimulation.
20220 citationsauthor #2
Cognition as a mediator for gait and balance impairments in GBA-related Parkinson’s disease
20227 citationsauthor #11
A Review on Response to Device-Aided Therapies Used in Monogenic Parkinsonism and GBA Variants Carriers: A Need for Guidelines and Comparative Studies
202210 citationsauthor #4
Protective association of HLA‐DRB1*04 subtypes in neurodegenerative diseases implicates acetylated tau PHF6 sequences
20228 citationsauthor #158
RIC3 variants are not associated with Parkinson’s disease in large European, Latin American, or East Asian cohorts
20213 citationsauthor #6
Diversity in Parkinson's disease genetics research: current landscape and future directions
20214 citationsauthor #21
The commercial genetic testing landscape for Parkinson's disease.
202122 citationsauthor #29
Polygenic risk prediction and SNCA haplotype analysis in a Latino Parkinson’s disease cohort
20219 citationsauthor #34
Navigating the open sea of commercial genetic testing in Parkinson's disease.
20211 citationsauthor #1
Tracing the Distribution of European Lactase Persistence Genotypes Along the Americas
20218 citationsauthor #24
Should we start integrating genetic data in decision-making on device-aided therapies in Parkinson disease? A point of view.
202116 citationsauthor #2
ATP1A3-Related Disorders: An Ever-Expanding Clinical Spectrum
202142 citationsauthor #2
Editorial: Genotype-Phenotype Correlation in Parkinsonian Conditions
20210 citationsauthor #2
Complement genes contribute sex-biased vulnerability in diverse illnesses
2020163 citationsauthor #332
Sensorimotor Inhibition and Mobility in Genetic Subgroups of Parkinson's Disease
20205 citationsauthor #10
When does postural instability appear in monogenic parkinsonisms? An individual-patient meta-analysis
202017 citationsauthor #11
Characterizing the Genetic Architecture of Parkinson's Disease in Latinos
202090 citationsauthor #37
Genetics of Parkinson’s disease in Brazil: a systematic review of monogenic forms
20206 citationsauthor #3
Neurodegenerative Motor Conditions
20200 citationsauthor #4
Multivariate prediction of dementia in Parkinson’s disease
202043 citationsauthor #3
Is it now time to routinely include genetic information in decision-making for device-aided therapies in Parkinson disease?
20200 citationsauthor #2
Novel compound heterozygous FBXO7 mutations in a family with early onset Parkinson's disease.
202010 citationsauthor #9
Genetic parkinsonisms and cancer: a systematic review and meta-analysis
202014 citationsauthor #6
Multivariate prediction of dementia in Parkinson’s disease
20207 citationsauthor #3
Dementia in Latin America: Paving the way toward a regional action plan
202096 citationsauthor #38
Genome‐Wide Analysis of Copy Number Variation in Latin American Parkinson's Disease Patients
202020 citationsauthor #36
Association of Subthalamic Deep Brain Stimulation With Motor, Functional, and Pharmacologic Outcomes in Patients With Monogenic Parkinson Disease
201972 citationsauthor #6
Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases.
2019187 citationsauthor #17
Genetics of cognitive trajectory in Brazilians: 15 years of follow-up from the Bambuí-Epigen Cohort Study of Aging
201910 citationsauthor #10
Diagnostic prediction model for levodopa-induced dyskinesia in Parkinson’s disease
201914 citationsauthor #7
Driving genotype treatment options down the right path(way)
20191 citationsauthor #2
The distribution and risk effect of GBA variants in a large cohort of PD patients from Colombia and Peru.
201940 citationsauthor #14
Genomic Dissection of Bipolar Disorder and Schizophrenia, Including 28 Subphenotypes.
2018659 citationsauthor #297
Sex differences in progression to mild cognitive impairment and dementia in Parkinson's disease.
2018130 citationsauthor #11
Age- and disease-dependent increase of the mitophagy marker phospho-ubiquitin in normal aging and Lewy body disease
2018112 citationsauthor #18
Erratum: Variable frequency of LRRK2 variants in the Latin American research consortium on the genetics of Parkinson’s disease (LARGE-PD), a case of ancestry
20180 citationsauthor #24
Association of a neuronal nitric oxide synthase gene polymorphism with levodopa-induced dyskinesia in Parkinson's disease.
20176 citationsauthor #4
The discovery of LRRK2 p.R1441S, a novel mutation for Parkinson's disease, adds to the complexity of a mutational hotspot
20172 citationsauthor #1
Intrafamilial variable phenotype including corticobasal syndrome in a family with p.P301L mutation in the MAPT gene: first report in South America.
201714 citationsauthor #9
Variable frequency of LRRK2 variants in the Latin American research consortium on the genetics of Parkinson’s disease (LARGE-PD), a case of ancestry
201734 citationsauthor #24
Erratum to: The discovery of LRRK2 p.R1441S, a novel mutation for Parkinson's disease, adds to the complexity of a mutational hotspot (American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, (2016), 171, 7, (925-930), 10.1002/ajmg.b.32452)
20173 citationsauthor #1
Large-scale exploratory genetic analysis of cognitive impairment in Parkinson's disease.
201732 citationsauthor #1
LARGE‐PD: Examining the genetics of Parkinson's disease in Latin America
201743 citationsauthor #2
GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease
2016197 citationsauthor #1
Some aspects of the validity of the Montreal Cognitive Assessment (MoCA) for evaluating cognitive impairment in Brazilian patients with Parkinson's disease
201627 citationsauthor #5
The discovery of LRRK2 p.R1441S, a novel mutation for Parkinson's disease, adds to the complexity of a mutational hotspot
201618 citationsauthor #1
Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease.
2016215 citationsauthor #27
Title The RAB 39 B p . G 192 R mutation causes X-linked dominant Parkinson ' s disease Permalink
20152 citationsauthor #1
Progressive Structural Brain Changes and NRG1 Gene Variants in First-Episode Nonaffective Psychosis
201512 citationsauthor #3
A Peruvian family with a novel PARK2 mutation: Clinical and pathological characteristics.
201525 citationsauthor #3
Dysbindin gene variability is associated with cognitive abnormalities in first-episode non-affective psychosis
201516 citationsauthor #2
The RAB39B p.G192R mutation causes X-linked dominant Parkinson’s disease
201595 citationsauthor #1
Cognitive profile of LRRK2‐related Parkinson's disease
201579 citationsauthor #26
Screening of cognitive impairment in patients with Parkinson's disease: diagnostic validity of the Brazilian versions of the Montreal Cognitive Assessment and the Addenbrooke's Cognitive Examination-Revised.
201537 citationsauthor #9
Association mapping of the PARK10 region for Parkinson's disease susceptibility genes.
201423 citationsauthor #4
A Disrupted-in-Schizophrenia 1 Gene Variant is Associated with Clinical Symptomatology in Patients with First-Episode Psychosis
201419 citationsauthor #2
The screening of the 3′UTR sequence of LRRK2 identified an association between the rs66737902 polymorphism and Parkinson’s disease
201415 citationsauthor #4
Identification of a Japanese family with LRRK2 p.R1441G-related Parkinson's disease.
201430 citationsauthor #4
Clinical and molecular studies reveal a PSEN1 mutation (L153V) in a Peruvian family with early-onset Alzheimer's disease.
20149 citationsauthor #4
APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease.
2014207 citationsauthor #1
Alpha-synuclein transcript isoforms in three different brain regions from Parkinson's disease and healthy subjects in relation to the SNCA rs356165/rs11931074 polymorphisms.
201437 citationsauthor #5
C9orf72 hexanucleotide repeat expansion and Guam amyotrophic lateral sclerosis-Parkinsonism-dementia complex.
201326 citationsauthor #3
Treatment of first-episode non-affective psychosis: a randomized comparison of aripiprazole, quetiapine and ziprasidone over 1 year
201320 citationsauthor #3
P3–014: A TOMM40 SNP in APOE‐ε4 noncarriers increases risk for multiple types of dementia
20131 citationsauthor #28
Progress in Neuro-Psychopharmacology & Biological Psychiatry
20130 citationsauthor #3
APOE ε4 increases risk for dementia in pure synucleinopathies.
2013343 citationsauthor #30
Prediction of acute clinical response following a first episode of non affective psychosis: results of a cohort of 375 patients from the Spanish PAFIP study.
201340 citationsauthor #5
Mutational Screening of PARKIN Identified a 3′ UTR Variant (rs62637702) Associated with Parkinson’s Disease
201311 citationsauthor #10
Predictors of clinical remission following a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables.
201336 citationsauthor #4
Aripiprazole, Ziprasidone and Quetiapine in the treatment of first-episode nonaffective psychosis: a 12-week randomized, flexible-dose, open-label trial.
201320 citationsauthor #3
Treatment of first-episode non-affective psychosis: a randomized comparison of aripiprazole, quetiapine and ziprasidone over 1 year
20133 citationsauthor #3
Aripiprazole, Ziprasidone, and Quetiapine in the Treatment of First-Episode Nonaffective Psychosis: Results of a 6-Week, Randomized, Flexible-Dose, Open-Label Comparison
201319 citationsauthor #3
P4‐377: A TOMM40 SNP IN APOE E4 NON‐CARRIERS INCREASES RISK FOR MULTIPLE TYPES OF DEMENTIA
20130 citationsauthor #27
P.1.a.012 Association between dysbindin gene and cerebral structures in a Spanish population
20130 citationsauthor #2
BDNF Val66Met variants and brain volume changes in non-affective psychosis patients and healthy controls: a 3 year follow-up study.
20138 citationsauthor #4
Homocysteine and cognition in first-episode psychosis patients
201246 citationsauthor #4
Predicting relapse after a first episode of non-affective psychosis: a three-year follow-up study.
2012146 citationsauthor #3
Common variation in the LRRK2 gene is a risk factor for Parkinson's disease
201217 citationsauthor #1
One year longitudinal study of the straight gyrus morphometry in first-episode schizophrenia-spectrum patients.
20128 citationsauthor #5
Clinical and Molecular Studies Reveal a PSEN1 Mutation (L153V) in a Peruvian Family with Early-Onset Alzheimer's Disease (P05.072)
20120 citationsauthor #4
Chapter 10 5-HT2A Polymorphisms and Negative Symptoms Response to Antipsychotic Treatment: Evidence of Association in First-Episode Psychosis Patients
20120 citationsauthor #3
A Search for SNCA 3′ UTR Variants Identified SNP rs356165 as a Determinant of Disease Risk and Onset Age in Parkinson’s Disease
201249 citationsauthor #8
Long-term effect of haloperidol, olanzapine, and risperidone on plasma prolactin levels in patients with first-episode psychosis.
201229 citationsauthor #2
GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology
2012150 citationsauthor #24
Risk prediction for complex diseases: application to Parkinson disease
201217 citationsauthor #3
Relapse prevention and remission attainment in first-episode non-affective psychosis. A randomized, controlled 1-year follow-up comparison of haloperidol, risperidone and olanzapine.
201126 citationsauthor #3
Effectiveness of haloperidol, risperidone and olanzapine in the treatment of first-episode non-affective psychosis: results of a randomized, flexible-dose, open-label 1-year follow-up comparison
201122 citationsauthor #3
Catechol-O-methyltransferase Val158Met polymorphism and negative symptoms after acute antipsychotic treatment in first-episode non-affective psychosis.
201130 citationsauthor #4
P.1.a.011 Association between BDNF gene and psychosis in a Spanish population
20110 citationsauthor #2
Insight dimensions in first‐episode psychosis patients: clinical, cognitive, pre‐morbid and socio‐demographic correlates
201138 citationsauthor #6
Long-term (3-year) effectiveness of haloperidol, risperidone and olanzapine: results of a randomized, flexible-dose, open-label comparison in first-episode nonaffective psychosis
201129 citationsauthor #3
Lrrk2 p.Q1111H substitution and Parkinson's disease in Latin America.
201118 citationsauthor #1
Sex-specific variation of MRI-based cortical morphometry in adult healthy volunteers: the effect on cognitive functioning.
201123 citationsauthor #4
Replication of MAPT and SNCA, but not PARK16‐18, as susceptibility genes for Parkinson's disease
201180 citationsauthor #1
Straight gyrus morphology in first-episode schizophrenia-spectrum patients.
20116 citationsauthor #5
170 – HIPPOCAMPUS-ACCUMBENS INTERACTIONS: THE CRITICAL ROLE OF MPFC
20110 citationsauthor #2
SO THAT WE MAY REST IN PEACE: DEATH NOTICES AND ONGOING BEREAVEMENT
20113 citationsauthor #1
Using structural equations to test for a direct effect of some antipsychotics on triglyceride levels in drug-naïve first-episode psychosis patients.
201110 citationsauthor #3
The UCHL1 S18Y polymorphism and Parkinson's disease in a Japanese population.
20118 citationsauthor #9

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT